
OrganiGram Holdings OGI
€ 1.12
-4.68%
Geschäftsbericht 2024
hinzugefügt 27.12.2025
Land |
|
IPO-Jahr |
- |
Branche |
Arzneimittelhersteller |
Börse |
NASDAQ GLOBAL |
Anteile |
- |
Marktkapitalisierung |
$ 402 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Andere Aktien der Branche "Arzneimittelhersteller"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | Nasdaq Global Market,SPB | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | Nasdaq Capital Market | ||
|
Avadel Pharmaceuticals plc
AVDL
|
$ 21.68 | 0.21 % | $ 2.06 B | Nasdaq Global Select Market | ||
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | Nasdaq Global Market | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | Nasdaq Capital Market | ||
|
Canopy Growth Corporation
CGC
|
$ 1.07 | -2.29 % | $ 115 M | Nasdaq Global Select Market | ||
|
Cronos Group
CRON
|
$ 2.63 | -1.13 % | $ 1.36 B | Nasdaq Global Market | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | NYSE,SPB | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | Nasdaq Global Market,SPB | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | Nasdaq Global Select Market,SPB | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 3.89 | 0.78 % | $ 54.7 M | Nasdaq Global Select Market | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | Nasdaq Global Select Market | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | NYSE | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | Nasdaq Capital Market | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | Nasdaq Capital Market | ||
|
Emergent BioSolutions
EBS
|
$ 11.11 | 0.59 % | $ 569 M | NYSE,SPB | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | Nasdaq Global Select Market | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | Nasdaq Global Select Market | ||
|
Evolus
EOLS
|
$ 4.26 | -4.16 % | $ 264 M | Nasdaq Global Market | ||
|
China Pharma Holdings
CPHI
|
$ 0.63 | -5.57 % | $ 11 M | NYSE American | ||
|
Harrow Health
HROW
|
$ 48.86 | 2.41 % | $ 1.59 B | Nasdaq Global Market | ||
|
Pacira BioSciences
PCRX
|
$ 21.74 | 2.35 % | $ 1.01 B | Nasdaq Global Select Market,SPB | ||
|
Perrigo Company plc
PRGO
|
$ 14.53 | 0.9 % | $ 2 B | NYSE | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | NYSE | ||
|
Bausch Health Companies
BHC
|
$ 6.06 | -1.46 % | $ 2.21 B | NYSE | ||
|
Sundial Growers
SNDL
|
$ 1.49 | 0.2 % | $ 3.37 M | Nasdaq Global Select Market | ||
|
Tilray
TLRY
|
$ 7.56 | -3.51 % | $ 4.67 B | Nasdaq Global Select Market | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Nasdaq Global Select Market | ||
|
Organogenesis Holdings
ORGO
|
$ 3.74 | -2.73 % | $ 492 M | Nasdaq Capital Market | ||
|
cbdMD
YCBD
|
$ 0.76 | -4.99 % | $ 3.28 M | NYSE American | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | Nasdaq Global Select Market,SPB | ||
|
Aurora Cannabis
ACB
|
$ 3.47 | -2.67 % | $ 86.3 M | NYSE | ||
|
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | Nasdaq Capital Market | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | Nasdaq Global Market | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | Nasdaq Global Select Market | ||
|
Rockwell Medical
RMTI
|
$ 1.09 | - | $ 25.4 M | Nasdaq Global Market | ||
|
Relmada Therapeutics
RLMD
|
$ 3.99 | -0.62 % | $ 120 M | Nasdaq Global Select Market,SPB | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | Nasdaq Global Select Market | ||
|
Assertio Holdings
ASRT
|
$ 11.82 | 1.2 % | $ 840 M | Nasdaq Capital Market | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | Nasdaq Capital Market | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 2.84 | 1.07 % | $ 3.52 M | Nasdaq Capital Market | ||
|
Solid Biosciences
SLDB
|
$ 6.33 | -8.73 % | $ 258 M | Nasdaq Global Select Market,SPB | ||
|
SCYNEXIS
SCYX
|
$ 0.82 | 0.57 % | $ 39.2 M | Nasdaq Global Select Market | ||
|
Veru
VERU
|
$ 2.38 | 3.03 % | $ 321 M | Nasdaq Capital Market | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | Nasdaq Global Select Market,SPB | ||
|
TherapeuticsMD
TXMD
|
$ 2.32 | -2.52 % | $ 24.2 M | Nasdaq Global Select Market | ||
|
Viatris
VTRS
|
$ 16.03 | 0.5 % | $ 19.4 B | Nasdaq Global Select Market,SPB | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | Nasdaq Global Market | ||
|
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | Nasdaq Global Market,SPB |